Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | FABP4 | P15090 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 5/20 | 0.35 |
| ▸ | PPARA | Q07869 | 3/20 | 0.34 |
| ▸ | WDR5 | P61964 | 3/20 | 0.34 |
| ▸ | IGF1R | P08069 | 1/20 | 0.34 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.33 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL977228 | 0.93 | PPARA (0.41) | FABP4SCN9APPARASCN7ASCN5A | |
| SCHEMBL978278 | 0.90 | FABP4 (0.37) | FABP4SCN9APPARASCN7ASCN5A | |
| SCHEMBL974202 | 0.90 | WDR5 (0.41) | FABP4SCN9APPARAWDR5SCN7A | |
| SCHEMBL975365 | 0.89 | PPARA (0.45) | FABP4SCN9APPARASCN5AL3MBTL1 | |
| SCHEMBL979148 | 0.88 | SCN9A (0.42) | FABP4SCN9ASCN7ASCN5A | |
| SCHEMBL977371 | 0.88 | FABP4 (0.41) | MEN1KMT2AFABP4SCN9APPARA | |
| SCHEMBL977867 | 0.88 | GRIA2 (0.35) | KMT2ASCN9ASCN7ASCN5ACA1 | |
| SCHEMBL977865 | 0.88 | GRIA2 (0.35) | KMT2ASCN9ASCN7ASCN5ACA1 | |
| SCHEMBL977039 | 0.87 | NHERF1 (0.40) | MEN1KMT2ASCN9ASCN7ASCN5A | |
| SCHEMBL975840 | 0.86 | PPARA (0.48) | MEN1KMT2AFABP4SCN9APPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130237513-A1 | AZETIDINE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY | SANOFI (FR) | 2013-09-12 | — | — | US | claimed |
| EP-2234966-B1 | AZETIDINE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY | SANOFI SA (FR) | 2013-09-11 | — | — | EP | claimed |
| US-20110009377-A1 | AZETIDINE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY | SANOFI-AVENTIS (FR) | 2011-01-13 | — | — | US | claimed |
| US-20130237513-A1 | AZETIDINE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY | SANOFI (FR) | 2013-09-12 | — | — | US | disclosed |
| US-8445478-B2 | Azetidine derivatives, their preparation and their application in therapy | SANOFI (FR) | 2013-05-21 | — | — | US | disclosed |
| US-20110009377-A1 | AZETIDINE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY | SANOFI-AVENTIS (FR) | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130237513-A1 | AZETIDINE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY | QDPR, AZI2, ADRA1B | MEN1 1111/4885KMT2A 2003/4885POLB 3591/4885 |
| US-20110009377-A1 | AZETIDINE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY | QDPR, AZI2, ADRA1B | MEN1 1111/4885KMT2A 2003/4885POLB 3591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.